© 2020 Palmetto GBA, LLC
We frequently update our articles to reflect the latest changes and updates to Medicare, and strongly recommend you visit this article at link below to confirm you have the latest version.
Printed Date: 9/22/2015
Dosage of erythropoietin stimulating agent has been reduced and maintained in response to hematocrit or hemoglobin level.
This modifier is used for national claims monitoring for ESAs administered in Medicare renal dialysis facilities, so therefore, is not applicable to Part B.
Reference: CMS Medicare Claims Processing Manual (Pub. 100-04), Chapter 8, Section 60.4 (PDF, 1.82 MB).
We value your opinion and want to provide the highest-quality and most relevant Medicare knowledge possible. Please let us know if this article was helpful.
It didn't answer my question
This article was helpful
We’re glad we could help you today and appreciate your feedback. When you rate our articles as most helpful, we know that we are on the right track for providing you with important news and information.
We're sorry this article didn't help you today. We'll use your feedback to review this article to try to revise or expand it. Contact us with more feedback or a question on this topic.
Last Updated: 05/03/2019